Dyadic Logo Current.jpg
Dyadic Announces Initiation of Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
24 janv. 2023 08h30 HE | Dyadic International, Inc.
JUPITER, Fla., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Pfizer and BioNTech
Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age
23 août 2022 06h45 HE | BioNTech SE
Updated analysis from 34 cases occurring at least seven days following a three-dose regimen showed 73.2% vaccine efficacy among children ages 6 months through 4 yearsThe vaccine efficacy remained...
Pfizer und BioNTech
Pfizer und BioNTech geben Update zur Wirksamkeit ihres COVID-19-Impfstoffs bei Kindern von 6 Monaten bis 4 Jahren
23 août 2022 06h45 HE | BioNTech SE
Daten einer weiterführenden Analyse mit 34 Fällen, die mindestens sieben Tage nach Verabreichung der primären Impfserie bestehend aus drei Dosen auftraten, zeigen eine Impfstoffwirksamkeit von 73,2 %...
Dr. William Haseltine releases new book on Innate Immunity and Covid-19
16 mars 2022 13h37 HE | ACCESS Health International
New York, March 16, 2022 (GLOBE NEWSWIRE) -- In his latest book, bestselling author William A. Haseltine Ph.D. tells us that understanding our natural immunity to the SARS-CoV-2 virus is critical...
190705_Biontech_Logo_RGB_Dark Green (Preferred)_0.png
Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of an Additional Booster Dose of their COVID-19 Vaccine for Older Adults
15 mars 2022 18h00 HE | BioNTech SE
Submission based on real-world safety and efficacy data from Israel Data showed rates of confirmed infections were 2 times lower and rates of severe illness were 4 times lower among individuals who...
Pfizer and BioNTech
Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age
25 janv. 2022 06h45 HE | BioNTech SE
First participants enrolled in clinical trial received Omicron-based vaccine candidate as a two-dose primary series and as a booster dose NEW YORK and MAINZ, GERMANY, JANUARY 25, 2022 — Pfizer Inc....
Pfizer und BioNTech
Pfizer und BioNTech beginnen klinische Studie zu Omikron-basiertem COVID-19-Impfstoff bei Erwachsenen im Alter von 18-55 Jahren
25 janv. 2022 06h45 HE | BioNTech SE
Die ersten Teilnehmer erhielten im Rahmen der klinischen Studie den Omikron-basierten Impfstoffkandidaten als Impfserie mit zwei Dosen oder als Auffrischungsimpfung NEW YORK und MAINZ, Deutschland,...
BioNTech and InstaDe
BioNTech and InstaDeep Developed and Successfully Tested Early Warning System to Detect Potential High-Risk SARS-CoV-2 Variants
11 janv. 2022 07h00 HE | BioNTech SE
Early Warning System combines Spike protein structural modeling with artificial intelligence (AI) to detect and monitor high-risk SARS-CoV-2 variants, identifying >90% of WHO-designated variants on...
BioNTech und InstaDe
BioNTech und InstaDeep entwickeln und testen erfolgreich ein Frühwarnsystem zur Erkennung potenzieller Hochrisikovarianten von SARS-CoV-2
11 janv. 2022 07h00 HE | BioNTech SE
Das Frühwarnsystem kombiniert Strukturmodellierung von Spike-Proteinen mit künstlicher Intelligenz (KI), um Hochrisikovarianten von SARS-CoV-2 zu erkennen und zu überwachen; dabei können...
Dyadic Logo Current.jpg
Dyadic Announces a NIIMBL Coronavirus Grant Under the White House’s American Rescue Plan
22 déc. 2021 09h12 HE | Dyadic International, Inc.
JUPITER, Fla., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further...